CAR T-cell study for relapsed multiple myeloma with GPRC5D
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 1 trial tests a CAR T-cell treatment made to target a protein called GPRC5D on myeloma cells. It may help patients whose multiple myeloma or plasma cell leukemia has come back or stopped responding to prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18–75 (men or women).
- Have relapsed or refractory multiple myeloma/plasma cell leukemia and have had at least 3 prior treatment types (including proteasome inhibitor chemotherapy and an immunomodulatory medicine).
- Your tumor must show GPRC5D on cells (checked by a bone marrow biopsy or other tumor sample using a lab test like immunohistochemistry or flow cytometry).
- You must have measurable active disease (for example, specific blood/urine protein levels or at least 10% certain plasma cells in bone marrow) and good overall breathing/blood oxygen.
- You must be able to do the study safely: ECOG 0–2, life expectancy at least 12 weeks, and acceptable blood counts, liver/kidney function, heart function, and blood clotting results.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a CAR T-cell treatment made to find a specific marker called GPRC5D on myeloma (or plasma cell leukemia) cells. It may help people whose disease has returned or hasn’t responded to several prior treatments.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
This trial tests a new type of immunotherapy called CAR T-cell therapy for people with multiple myeloma that has returned or not responded to standard treatments. The therapy uses your own immune cells, modified to attack the cancer, which may help you achieve a remission.
This trial tests a new treatment using your own immune cells (called CAR-T cells) to fight multiple myeloma that has returned or not responded to earlier treatments. The treatment is designed to target and kill myeloma cells more effectively.
This trial tests a new type of immune cell therapy (CAR-T cells boosted with a protein called IL-15) for people with multiple myeloma or plasma cell leukemia that has not responded to standard treatments or has come back. The goal is to see if these enhanced cells can better fight the cancer.
This study tests a new type of cell therapy called BCMA-GPRC5D CAR-T for people whose multiple myeloma has come back or not responded to standard treatments. The therapy uses your own immune cells, modified in a lab, to find and attack myeloma cells.
Hear when a new Relapsed/Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.